In a report released on September 11, Gabriele Berti from Intesa Sanpaolo maintained a Buy rating on Esprinet Spa, with a price target of €6.70.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gabriele Berti has given his Buy rating due to a combination of factors that highlight Esprinet Spa’s strong performance and strategic positioning. The company’s robust second-quarter results, with a significant increase in both revenue and adjusted EBITDA, demonstrate the effectiveness of its focus on high-margin businesses such as V-Valley and Zeliatech. This strategic emphasis has not only improved gross margins but also contributed to a notable rise in net income.
Furthermore, the positive market conditions in Southern Europe, particularly in Iberia, have supported Esprinet’s growth, while management’s confidence in achieving the upper end of their FY25 guidance range adds to the stock’s attractiveness. The company’s proactive measures to enhance liquidity and optimize its portfolio by reducing working capital-intensive activities further strengthen its financial position. These elements combined have led to an upward revision of estimates and a reaffirmed Buy rating from Gabriele Berti.
In another report released on September 13, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a €6.50 price target.
0NFS’s price has also changed moderately for the past six months – from EUR4.579 to EUR5.150, which is a 12.47% increase.